HUE058855T2 - Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával - Google Patents
Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásávalInfo
- Publication number
- HUE058855T2 HUE058855T2 HUE12745883A HUE12745883A HUE058855T2 HU E058855 T2 HUE058855 T2 HU E058855T2 HU E12745883 A HUE12745883 A HU E12745883A HU E12745883 A HUE12745883 A HU E12745883A HU E058855 T2 HUE058855 T2 HU E058855T2
- Authority
- HU
- Hungary
- Prior art keywords
- antibody
- combination therapy
- purine analogue
- purine
- analogue
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523862P | 2011-08-16 | 2011-08-16 | |
| EP11177660 | 2011-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE058855T2 true HUE058855T2 (hu) | 2022-09-28 |
Family
ID=47714800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12745883A HUE058855T2 (hu) | 2011-08-16 | 2012-08-14 | Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20140227277A1 (enExample) |
| EP (2) | EP2744826B1 (enExample) |
| JP (1) | JP6114273B2 (enExample) |
| KR (3) | KR20140071368A (enExample) |
| CN (1) | CN103703027B (enExample) |
| AU (1) | AU2012296905B2 (enExample) |
| BR (1) | BR112013033916B1 (enExample) |
| CA (1) | CA2841738C (enExample) |
| CY (1) | CY1125148T1 (enExample) |
| DK (1) | DK2744826T3 (enExample) |
| ES (1) | ES2909720T3 (enExample) |
| HR (1) | HRP20220224T1 (enExample) |
| HU (1) | HUE058855T2 (enExample) |
| IL (1) | IL230295B (enExample) |
| LT (1) | LT2744826T (enExample) |
| MX (1) | MX353589B (enExample) |
| PL (1) | PL2744826T3 (enExample) |
| PT (1) | PT2744826T (enExample) |
| RS (1) | RS63121B1 (enExample) |
| RU (1) | RU2664462C9 (enExample) |
| SG (1) | SG10201606788VA (enExample) |
| SI (1) | SI2744826T1 (enExample) |
| SM (1) | SMT202200160T1 (enExample) |
| WO (1) | WO2013024095A1 (enExample) |
| ZA (1) | ZA201401835B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2514591A (en) * | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| ES2523901B1 (es) * | 2013-05-31 | 2015-12-02 | Universidad Autónoma de Madrid | Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica |
| IL249533A0 (en) * | 2014-06-16 | 2017-02-28 | Xencor Inc | Treatment of chronic lymphocytic leukemia |
| US20170137516A1 (en) * | 2014-06-16 | 2017-05-18 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| SMT201900647T1 (it) | 2015-05-26 | 2020-01-14 | Morphosys Ag | Combinazione di un anticorpo anti-cd19 e un inibitore della tirosina chinasi di bruton e suoi usi |
| WO2017032679A1 (en) * | 2015-08-21 | 2017-03-02 | Morphosys Ag | Combinations and uses thereof |
| LT3916392T (lt) * | 2016-05-30 | 2024-08-26 | Incyte Corporation | Pacientų gydymo anti-cd19 terapinės naudos prognozavimo būdai |
| AU2017348624B2 (en) | 2016-10-28 | 2024-09-26 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| BR112019025034A2 (pt) | 2017-05-31 | 2020-06-30 | Morphosys Ag | combinação |
| JP7279011B2 (ja) | 2017-07-10 | 2023-05-22 | インターナショナル－ドラッグ－ディベロップメント－バイオテック | 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療 |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| WO2020150513A1 (en) * | 2019-01-17 | 2020-07-23 | Fred Hutchinson Cancer Research Center | Methods to enhance the selectivity and effectiveness of cancer treatments |
| US20230357392A1 (en) * | 2021-12-22 | 2023-11-09 | Morphosys Ag | Treatment Paradigm for an Anti-CD19 Antibody Therapy |
| WO2025012080A1 (en) | 2023-07-13 | 2025-01-16 | Christian-Albrechts-Universität Zu Kiel | Humanized anti-cd7 antibody |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11852A (en) | 1854-10-31 | Abraham bassford | ||
| US106A (en) | 1915-08-24 | Specipication | ||
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| HK1041221A1 (zh) * | 1998-08-11 | 2002-07-05 | Idec药物公司 | 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法 |
| HK1046635B (en) * | 1999-06-09 | 2009-10-09 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| WO2002022212A2 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
| JP5215180B2 (ja) | 2005-06-20 | 2013-06-19 | メダレックス インコーポレーティッド | Ｃｄ１９抗体およびその使用法 |
| WO2007064911A1 (en) * | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| ATE509954T1 (de) * | 2005-12-30 | 2011-06-15 | Merck Patent Gmbh | Anti-cd19-antikörper mit reduzierter immunogenität |
| ES2402591T3 (es) * | 2006-08-14 | 2013-05-07 | Xencor Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
| US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| ES2659517T3 (es) * | 2007-05-30 | 2018-03-16 | Xencor, Inc. | Métodos y composiciones para inhibir células que expresan CD32B |
| SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| AU2010263272C1 (en) | 2009-06-24 | 2016-02-11 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
| RU2012109451A (ru) * | 2009-08-14 | 2013-09-27 | Роше Гликарт Аг | Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном |
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| CN102711479A (zh) * | 2009-11-06 | 2012-10-03 | 无限药品股份有限公司 | Hedgehog通道抑制剂的口服制剂 |
-
2012
- 2012-08-14 PT PT127458834T patent/PT2744826T/pt unknown
- 2012-08-14 KR KR1020147006942A patent/KR20140071368A/ko not_active Ceased
- 2012-08-14 JP JP2014525432A patent/JP6114273B2/ja active Active
- 2012-08-14 LT LTEPPCT/EP2012/065904T patent/LT2744826T/lt unknown
- 2012-08-14 HR HRP20220224TT patent/HRP20220224T1/hr unknown
- 2012-08-14 KR KR1020197022418A patent/KR102117202B1/ko active Active
- 2012-08-14 PL PL12745883T patent/PL2744826T3/pl unknown
- 2012-08-14 HU HUE12745883A patent/HUE058855T2/hu unknown
- 2012-08-14 US US14/127,217 patent/US20140227277A1/en not_active Abandoned
- 2012-08-14 CA CA2841738A patent/CA2841738C/en active Active
- 2012-08-14 WO PCT/EP2012/065904 patent/WO2013024095A1/en not_active Ceased
- 2012-08-14 RU RU2014103490A patent/RU2664462C9/ru active
- 2012-08-14 SI SI201231992T patent/SI2744826T1/sl unknown
- 2012-08-14 CN CN201280036572.4A patent/CN103703027B/zh active Active
- 2012-08-14 AU AU2012296905A patent/AU2012296905B2/en active Active
- 2012-08-14 DK DK12745883.4T patent/DK2744826T3/da active
- 2012-08-14 EP EP12745883.4A patent/EP2744826B1/en active Active
- 2012-08-14 KR KR1020207014644A patent/KR20200060779A/ko not_active Withdrawn
- 2012-08-14 SG SG10201606788VA patent/SG10201606788VA/en unknown
- 2012-08-14 RS RS20220314A patent/RS63121B1/sr unknown
- 2012-08-14 ES ES12745883T patent/ES2909720T3/es active Active
- 2012-08-14 EP EP22155604.6A patent/EP4083071A3/en active Pending
- 2012-08-14 BR BR112013033916-0A patent/BR112013033916B1/pt active IP Right Grant
- 2012-08-14 SM SM20220160T patent/SMT202200160T1/it unknown
- 2012-08-14 MX MX2013014935A patent/MX353589B/es active IP Right Grant
-
2014
- 2014-01-02 IL IL230295A patent/IL230295B/en active IP Right Grant
- 2014-03-12 ZA ZA2014/01835A patent/ZA201401835B/en unknown
-
2020
- 2020-04-03 US US16/839,903 patent/US20200352975A1/en not_active Abandoned
-
2022
- 2022-04-14 CY CY20221100284T patent/CY1125148T1/el unknown
-
2024
- 2024-02-20 US US18/581,959 patent/US20240424012A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE058855T2 (hu) | Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával | |
| HUS2100034I1 (hu) | ANGPTL3-ellenes antitestek és alkalmazásaik | |
| LTC2635601I2 (lt) | Antikūnai prieš il-23 | |
| HUE044591T2 (hu) | Anti-CD40 antitestek és alkalmazásuk | |
| LT2794654T (lt) | Anti-phf-tau antikūnai ir jų panaudojimas | |
| HUE054437T2 (hu) | Anti-CGRP készítmények és alkalmazásuk | |
| DK3275892T3 (da) | Præfusions-rsv-f-antigener | |
| IL231777A0 (en) | Antibodies against tl1a and uses thereof | |
| HUE037700T2 (hu) | OX40-hez kötõdõ ellenanyagok és felhasználásuk | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| DK3091029T5 (da) | Anti-IL13-antistofformuleringer | |
| SMT202000512T1 (it) | Anticorpi anti-tau umani | |
| HUE13746964T2 (hu) | CD47 antitestek és alkalmazási eljárásaik | |
| HUE053720T2 (hu) | ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra | |
| HRP20181457T1 (hr) | Anti-htra1 protutijela i postupci uporabe | |
| IL232213A0 (en) | Antibody Formulations and Methods | |
| HUE039175T2 (hu) | Ragasztóanyag és az annak alkalmazásával elõállított termék | |
| CO6801637A2 (es) | Formulaciones de anticuerpos | |
| DK2760886T3 (da) | Immunocytokin-kombinationsterapi | |
| BR112015021077A2 (pt) | artigo catalítico com washcoat segregado e métodos para fabricação do mesmo. | |
| EP2710926A4 (en) | Simple self-assembly chair for health | |
| HUE042008T2 (hu) | Prosztataspecifikus õssejt antigén elleni antitestek és alkalmazásuk | |
| BR112013032688A2 (pt) | artigo, e, cigarro | |
| DK3068802T3 (da) | Antistof mod gd2-o-acetyleret-gangliosid med pro-apoptotisk aktivitet | |
| HRP20180685T1 (hr) | Antitijelo protiv humanog dlk-1 koje posjeduje protutumorsko djelovanje in vivo |